-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Underperform on Harmony Biosciences Hldgs, Lowers Price Target to $28

Benzinga·02/25/2026 09:58:25
Listen to the news
B of A Securities analyst Jason Gerberry maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Underperform and lowers the price target from $32 to $28.